The combination treatment of CDDP and trigonelline treated breast cancers efficiently in the in vivo mouse model, and the TCGA breast cancer data showed that Nrf2 is an important index of the survival rate of patients. This evidence concerns the gene NFE2L2 and breast carcinoma.